Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Hypercholesterolemia: HELP
Christopher P. Cannon
Based on 13 articles published since 2009
(Why 13 articles?)
||||
Expertise Level
The expertise of Christopher P. Cannon ranks in the
  • Top 0.12%
  • ... of 27,392 published authors worldwide on Hypercholesterolemia
  • ... from 2009 through 2019
  • ... based on contributions to 13 articles on the topic.
Graphical view (beta)
Get your prestigious
Expert badge
similar to this:
 
Work Locations
Details
Most likely:    Harvard University Boston   Contact    
2018
  • CGH Medical Center, Sterling, Illinois, USA; and Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: · Vanderbilt University School of Medicine, Nashville, Tennessee, USA. · Harvard Clinical Research Institute, Boston, Massachusetts, USA. · University of Edinburgh, Edinburgh, UK. · Perelman School of Medicine, Smilow Centre for Translational Research, Philadelphia, Pennsylvania, USA. · Section of Nephrology, Boston University School of Medicine, Boston, Massachusetts, USA. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. · Sanofi, Bridgewater, New Jersey, USA. · Sanofi, Chilly-Mazarin, France. · Sanofi, Chilly-Mazarin, France; IviData Stats, Levallois-Perret, Paris, France. · Department of Hypertension, Medical University of Lodz, Lodz, Poland. · Pubmed 29526502
2017
  • Cardiovascular Center of Sarasota, Sarasota, Florida. Electronic address: · Harvard Clinical Research Institute, Boston, Massachusetts. · Division of Lipidology, Department of Medicine, University of Cape Town and MRC Cape Heart Group, Cape Town, South Africa. · Virginia Commonwealth University and National Clinical Research, Inc., Richmond, Virginia. · L'Institut du Thorax, CHU de Nantes, Nantes, France. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York. · Sanofi, Bridgewater, New Jersey. · University of Edinburgh, Edinburgh, UK. · Pubmed 28750828
  • Baim Institute for Clinical Research, Boston, Massachusetts. · Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. · Global Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey. · Axtria, Berkeley Heights, New Jersey. · Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts. · Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Program Direction, Cardiovascular and Metabolism, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Pubmed 28768335
2016
  • Sanofi, Paris, France. · Sanofi, Paris, France · Sanofi, Frankfurt, Germany. · Sanofi, Montpellier, France. · Regeneron Pharmaceuticals, Inc, Tarrytown, NY. · Harvard Clinical Research Institute, Boston, MA. · Sanofi, Bridgewater, NJ. · Pubmed 27287699
2015
  • Harvard Clinical Research Institute, Boston, MA, USA Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA · Harvard Clinical Research Institute, Boston, MA, USA Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. · Pubmed 25971287
  • The Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH. Electronic address: · University of Iowa, Iowa City, IA. · Harvard Clinical Research Institute, Boston, MA. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc, Tarrytown, NY. · Sanofi, Bridgewater, NJ. · University of Dundee, Dundee, Scotland, United Kingdom. · Pubmed 26027630
  • Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: · Hartford Hospital, Hartford, CT, USA. · Harvard Clinical Research Institute, Boston, MA, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, MA, USA. · Duke University Medical Center, Durham, NC, USA. · Lipid Clinic, Centre Hospitalier Universitaire de Québec, Laval University, Québec, Canada. · McGuire VA Medical Center, Richmond, VA, USA. · Groupe Hospitalier Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France. · Department of Medicine, Emory University, Atlanta, GA, USA. · Mayo Clinic, Department of Cardiovascular Diseases, Rochester, MN, USA. · PCSK9 Development and Launch Unit, Sanofi, Montpellier, France. · Department of Biostatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Department of Clinical Sciences, Cardiovascular & Metabolism Therapeutics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Pubmed 26687696
  • Harvard Clinical Research Institute, 930 W. Commonwealth Ave, Boston, MA 02215, USA · Department of Endocrinology, L'Institut du Thorax, CHU de Nantes, Nantes, France. · Division of Lipidology, Department of Medicine, University of Cape Town and MRC Cape Heart Group, Cape Town, South Africa. · Virginia Commonwealth University and National Clinical Research, Inc., Richmond, VA, USA. · Sanofi, Paris, France. · Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Sanofi, Bridgewater, NJ, USA. · University of Dundee, Dundee, UK. · Pubmed 25687353
2014
  • Office of the Vice President, Weill Cornell Medical College, New York, NY, USA · Merck Research Laboratories, Rahway, NJ, USA. · Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. · Utah Foundation for Biomedical Research and Utah Lipid Center, Salt Lake City, UT, USA. · Office of the Vice President, Weill Cornell Medical College, New York, NY, USA. · Centre for Vascular Research, University of New South Wales, Sydney, Australia, USA. · Pubmed 24737712
Probable:    Miscellaneous institutions in Boston      
2017
  • Baim Institute for Clinical Research, Boston, Massachusetts. · Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. · Global Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey. · Axtria, Berkeley Heights, New Jersey. · Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts. · Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Program Direction, Cardiovascular and Metabolism, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Pubmed 28768335
Possible:    SUNY Buffalo   Contact    
2010
  • Department of Medicine, SUNY at Buffalo School of Medicine, Buffalo, NY, USA. · Pubmed 20802270
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 13 total) written by Christopher P. Cannon about Hypercholesterolemia:

  • Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. 2018
  • Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). 2017
  • Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. 2017
  • Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. 2016
  • Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? 2016
  • PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. 2015
  • Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. 2015
  • Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. 2015
  • Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. 2015
  • Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. 2014
Show List of Full Article Records
Google Searches

Learn more about Christopher P. Cannon using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Harvard University Boston
Miscellaneous institutions in Boston
SUNY Buffalo
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Harvard University Boston
2018
  • CGH Medical Center, Sterling, Illinois, USA; and Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: · Vanderbilt University School of Medicine, Nashville, Tennessee, USA. · Harvard Clinical Research Institute, Boston, Massachusetts, USA. · University of Edinburgh, Edinburgh, UK. · Perelman School of Medicine, Smilow Centre for Translational Research, Philadelphia, Pennsylvania, USA. · Section of Nephrology, Boston University School of Medicine, Boston, Massachusetts, USA. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. · Sanofi, Bridgewater, New Jersey, USA. · Sanofi, Chilly-Mazarin, France. · Sanofi, Chilly-Mazarin, France; IviData Stats, Levallois-Perret, Paris, France. · Department of Hypertension, Medical University of Lodz, Lodz, Poland. · Pubmed 29526502
2017
  • Cardiovascular Center of Sarasota, Sarasota, Florida. Electronic address: · Harvard Clinical Research Institute, Boston, Massachusetts. · Division of Lipidology, Department of Medicine, University of Cape Town and MRC Cape Heart Group, Cape Town, South Africa. · Virginia Commonwealth University and National Clinical Research, Inc., Richmond, Virginia. · L'Institut du Thorax, CHU de Nantes, Nantes, France. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York. · Sanofi, Bridgewater, New Jersey. · University of Edinburgh, Edinburgh, UK. · Pubmed 28750828
  • Baim Institute for Clinical Research, Boston, Massachusetts. · Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. · Global Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey. · Axtria, Berkeley Heights, New Jersey. · Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts. · Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Program Direction, Cardiovascular and Metabolism, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Pubmed 28768335
2016
  • Sanofi, Paris, France. · Sanofi, Paris, France · Sanofi, Frankfurt, Germany. · Sanofi, Montpellier, France. · Regeneron Pharmaceuticals, Inc, Tarrytown, NY. · Harvard Clinical Research Institute, Boston, MA. · Sanofi, Bridgewater, NJ. · Pubmed 27287699
2015
  • Harvard Clinical Research Institute, Boston, MA, USA Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA · Harvard Clinical Research Institute, Boston, MA, USA Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. · Pubmed 25971287
  • The Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH. Electronic address: · University of Iowa, Iowa City, IA. · Harvard Clinical Research Institute, Boston, MA. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc, Tarrytown, NY. · Sanofi, Bridgewater, NJ. · University of Dundee, Dundee, Scotland, United Kingdom. · Pubmed 26027630
  • Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: · Hartford Hospital, Hartford, CT, USA. · Harvard Clinical Research Institute, Boston, MA, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, MA, USA. · Duke University Medical Center, Durham, NC, USA. · Lipid Clinic, Centre Hospitalier Universitaire de Québec, Laval University, Québec, Canada. · McGuire VA Medical Center, Richmond, VA, USA. · Groupe Hospitalier Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France. · Department of Medicine, Emory University, Atlanta, GA, USA. · Mayo Clinic, Department of Cardiovascular Diseases, Rochester, MN, USA. · PCSK9 Development and Launch Unit, Sanofi, Montpellier, France. · Department of Biostatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Department of Clinical Sciences, Cardiovascular & Metabolism Therapeutics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Pubmed 26687696
  • Harvard Clinical Research Institute, 930 W. Commonwealth Ave, Boston, MA 02215, USA · Department of Endocrinology, L'Institut du Thorax, CHU de Nantes, Nantes, France. · Division of Lipidology, Department of Medicine, University of Cape Town and MRC Cape Heart Group, Cape Town, South Africa. · Virginia Commonwealth University and National Clinical Research, Inc., Richmond, VA, USA. · Sanofi, Paris, France. · Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Sanofi, Bridgewater, NJ, USA. · University of Dundee, Dundee, UK. · Pubmed 25687353
2014
  • Office of the Vice President, Weill Cornell Medical College, New York, NY, USA · Merck Research Laboratories, Rahway, NJ, USA. · Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. · Utah Foundation for Biomedical Research and Utah Lipid Center, Salt Lake City, UT, USA. · Office of the Vice President, Weill Cornell Medical College, New York, NY, USA. · Centre for Vascular Research, University of New South Wales, Sydney, Australia, USA. · Pubmed 24737712
Miscellaneous institutions in Boston
2017
  • Baim Institute for Clinical Research, Boston, Massachusetts. · Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. · Global Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey. · Axtria, Berkeley Heights, New Jersey. · Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts. · Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Program Direction, Cardiovascular and Metabolism, Regeneron Pharmaceuticals, Inc, Tarrytown, New York. · Pubmed 28768335
SUNY Buffalo
2010
  • Department of Medicine, SUNY at Buffalo School of Medicine, Buffalo, NY, USA. · Pubmed 20802270
Yearly article counts 01224102010
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.